FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Susumu Nakata

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Disorders

Prostatic Neoplasms

Co-author Network

Publications

TOP 3
Mano Horinaka; Susumu Nakata; Takumi Shiraishi; Mitsuhiro Tomosugi; Miki Wakada; Tatsushi Yoshida; Sae Yoshikawa; Toshiyuki Sakai
Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Tatsushi Yoshida; Takumi Shiraishi; Mano Horinaka; Susumu Nakata; Takashi Yasuda; Ahmed E Goda; Miki Wakada; Yoichi Mizutani; Tsuneharu Miki; Akiyoshi Nishikawa; Toshiyuki Sakai
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Junji Kouhara; Tatsushi Yoshida; Susumu Nakata; Mano Horinaka; Miki Wakada; Yuji Ueda; Hisakazu Yamagishi; Toshiyuki Sakai
Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Susumu Nakata (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Mano Horinaka; Susumu Nakata; Takumi Shiraishi; Mitsuhiro Tomosugi; Miki Wakada; Tatsushi Yoshida; Sae Yoshikawa; Toshiyuki Sakai
Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Cancer science 2012;103(2):282-7.
2007: Tatsushi Yoshida; Takumi Shiraishi; Mano Horinaka; Susumu Nakata; Takashi Yasuda; Ahmed E Goda; Miki Wakada; Yoichi Mizutani; Tsuneharu Miki; Akiyoshi Nishikawa; Toshiyuki Sakai
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Cancer science 2007;98(9):1417-23.
2007: Junji Kouhara; Tatsushi Yoshida; Susumu Nakata; Mano Horinaka; Miki Wakada; Yuji Ueda; Hisakazu Yamagishi; Toshiyuki Sakai
Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.
International journal of oncology 2007;30(3):679-87.
2006: Susumu Nakata; Tatsushi Yoshida; Takumi Shiraishi; Mano Horinaka; Junji Kouhara; Miki Wakada; Toshiyuki Sakai
15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Molecular cancer therapeutics 2006;5(7):1827-35.
2006: Mano Horinaka; Tatsushi Yoshida; Takumi Shiraishi; Susumu Nakata; Miki Wakada; Toshiyuki Sakai
The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand.
Molecular cancer therapeutics 2006;5(4):945-51.
2005: Mano Horinaka; Tatsushi Yoshida; Takumi Shiraishi; Susumu Nakata; Miki Wakada; Ryoko Nakanishi; Hoyoku Nishino; Hiroshi Matsui; Toshiyuki Sakai
Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells.
Oncogene 2005;24(48):7180-9.
2005: Tatsushi Yoshida; Ayaka Maeda; Mano Horinaka; Takumi Shiraishi; Susumu Nakata; Miki Wakada; Shingo Yogosawa; Toshiyuki Sakai
Quercetin induces gadd45 expression through a p53-independent pathway.
Oncology reports 2005;14(5):1299-303.
2005: Mano Horinaka; Tatsushi Yoshida; Takumi Shiraishi; Susumu Nakata; Miki Wakada; Ryoko Nakanishi; Hoyoku Nishino; Toshiyuki Sakai
The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells.
Biochemical and biophysical research communications 2005;333(3):833-8.
2005: Takumi Shiraishi; Tatsushi Yoshida; Susumu Nakata; Mano Horinaka; Miki Wakada; Yoichi Mizutani; Tsuneharu Miki; Toshiyuki Sakai
Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Cancer research 2005;65(14):6364-70.
2005: Tatsushi Yoshida; Takumi Shiraishi; Susumu Nakata; Mano Horinaka; Miki Wakada; Yoichi Mizutani; Tsuneharu Miki; Toshiyuki Sakai
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
Cancer research 2005;65(13):5662-7.
2005: Takumi Shiraishi; Tatsushi Yoshida; Susumu Nakata; Mano Horinaka; Miki Wakada; Yoichi Mizutani; Tsuneharu Miki; Toshiyuki Sakai
Differential response at the hGABP/E4TF1 site of retinoblastoma gene promoter in human testicular seminoma cells.
Oncology reports 2005;13(5):871-4.
2004: Susumu Nakata; Tatsushi Yoshida; Mano Horinaka; Takumi Shiraishi; Miki Wakada; Toshiyuki Sakai
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Oncogene 2004;23(37):6261-71.